SEC Filing Summary: BioTime, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2009. BioTime, Inc. is a biotechnology company operating in two primary segments: blood plasma volume expanders (primarily Hextend) and regenerative medicine (stem cell technology). The company markets research products through its subsidiary, Embryome Sciences, Inc., and is developing therapeutic products through new subsidiaries, OncoCyte Corporation and BioTime Asia, Limited.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenues | $446,993 | $1,175,827 |
| Net Loss | $(3,574,755) | $(6,564,339) |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.24) |
| Cash and Cash Equivalents | $7,942,577 (as of Sep 30, 2009) | N/A |
| Lines of Credit Payable (Net) | $135,455 | N/A |
| Shareholders' Equity | $4,146,460 | N/A |
Note: The company moved from a shareholders' deficit of $(4,346,814) at year-end 2008 to positive equity of $4,146,460 at September 30, 2009, primarily due to equity issuances.
Material Changes vs. Prior Period
- Revenue: Total revenues for the nine months ended September 30, 2009, decreased slightly to $1.18 million from $1.22 million in the prior year period. Royalty revenue from product sales declined 19% year-over-year ($799,910 vs. $991,444), attributed to decreased sales to the U.S. Armed Forces. However, the company recognized $151,699 in grant income from the California Institute of Regenerative Medicine (CIRM), a new revenue stream not present in the prior year.
- Expenses: Operating expenses increased significantly. General and administrative expenses rose to $4.52 million for the nine months ended September 30, 2009, from $1.76 million in the prior year. This increase was driven largely by a $1.97 million increase in stock appreciation rights compensation liability and higher stock-based compensation.
- Liquidity: Cash and cash equivalents increased dramatically from $12,279 at December 31, 2008, to $7.94 million at September 30, 2009. This was achieved through $8.0 million in proceeds from the issuance of common shares and $2.31 million in new borrowings under the line of credit.
- Debt: The company executed an exchange offer in August 2009, converting approximately $3.35 million of revolving credit notes into common shares and warrants, significantly reducing outstanding debt.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that operating revenues will continue to depend on royalties from Hextend sales until regenerative medicine products are commercialized. The company expects to launch 35 additional cell lines and growth media with distributor Millipore Corporation within the next 12 months.
- Financing Needs: While the company has raised capital recently, it notes that future operations depend on the availability of additional financing. OncoCyte Corporation raised $2.0 million in October 2009 but will require substantial additional capital for development.
- Risks: Key risks include the uncertainty of clinical trial results, regulatory approval (FDA) for therapeutic products, competition, and the ability to secure future financing. The company has substantial net operating loss carryovers and has provided a 100% valuation allowance for deferred taxes.
- Unusual Items: A significant portion of the increase in General and Administrative expenses was due to non-cash stock appreciation rights compensation liability. Additionally, interest expense included an imputed cost related to the beneficial conversion feature of the line of credit.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $7.94 million cash balance against the reported net cash burn of approximately $3.4 million for the nine-month period.
- Debt Maturity: Confirm the status of the remaining $150,000 in revolving credit notes maturing on December 1, 2009, and the terms for conversion to equity.
- Grant Revenue Recognition: Review the terms of the $4.7 million CIRM grant to understand the timing of future revenue recognition versus cash receipt.
- Equity Dilution: Assess the impact of outstanding warrants (approximately 12.8 million as of September 30, 2009) and recent share issuances on future earnings per share.
- Subsidiary Funding: Monitor the capital requirements of the new subsidiaries, OncoCyte and BioTime Asia, which are in early-stage development.